| European Case Law Identifier: | ECLI:EP:BA:2012:T022311.20120522 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 22 May 2012 | ||||||||
| Case number: | T 0223/11 | ||||||||
| Application number: | 03722591.9 | ||||||||
| IPC class: | A61P 19/10 A61K 31/663 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Ibandronic acid for the treatment and prevention of osteoporosis | ||||||||
| Applicant name: | F. Hoffmann-La Roche AG | ||||||||
| Opponent name: | Laboratorios Liconsa, S.A. Alfred E. Tiefenbacher GmbH & Co. KG Teva Pharmaceutical Industries LTD. Gedeon Richter Plc. Generics [UK] Limited Synthon BV Intervener: Sandoz Farmacêutica, Lda. |
||||||||
| Board: | 3.3.02 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | All requests: added subject-matter (yes) Admissibility of intervention (no) Referral to the Enlarged Board of Appeal (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t110223eu1.html
Date retrieved: 17 May 2021